{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:06:25Z","timestamp":1779955585831,"version":"3.53.1"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized, posing significant challenges to effective management. This review summarizes current United States Food and Drug Administration \u2013approved therapies and management guidelines of the American College of Rheumatology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Contemporary SLE management is guided by organ systems involvement and disease severity. Discoveries of molecular mechanisms underlying disease pathogenesis have driven the development of targeted biologic therapies, including natural and engineered antibodies, chimeric antigen receptor\u2013guided cell therapies, and T-cell engagers, transforming the therapeutic landscape of lupus. In addition to traditional B-cell and plasma cell surface targets, emerging molecular targets include transmembrane signaling molecules such as CD40L and intracellular organelles such as endosomes and mitochondria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>While antibody and cell-based biologic therapies target pathogenesis-driving molecules, they suppress key immune pathways and thus infection remains a leading cause of morbidity and mortality. Accordingly, this review also addresses nonpharmacologic strategies \u2013 such as dietary modifications \u2013 that may confer therapeutic benefit without increasing susceptibility to infection. With a rapidly expanding portfolio of mechanistically driven clinical trials, the future of SLE management appears increasingly promising.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001160","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:00:09Z","timestamp":1775289609000},"page":"282-296","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenesis-directed lupus therapeutics"],"prefix":"10.1097","volume":"38","author":[{"given":"Bhavya","family":"Poudyal","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Perl","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine"},{"name":"Department of Microbiology and Immunology, and Biochemistry and Molecular Biology, Department of Pathology, State University of New York, Upstate Medical University, College of Medicine, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"R1-20260528","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-857X(21)00942-X","article-title":"The history of lupus erythematosus","volume":"14","author":"Smith","year":"1988","journal-title":"Rheum Dis Clin N Am"},{"key":"R3-20260528","article-title":"2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"152786","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/art.41683","article-title":"American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity","volume":"73","author":"Rosenbaum","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/acr.25528","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1191\/0961203305lu2138oa","article-title":"Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases","volume":"14","author":"Chambers","year":"2005","journal-title":"Lupus"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2665-9913(24)00338-2","article-title":"Evolution and trajectory of B-cell targeted therapies in rheumatic diseases","volume":"7","author":"Carter","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20260528","first-page":"575","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FJC.0000000000000839","article-title":"Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness, and safety","volume":"76","author":"Correia","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP Randomized Clinical Trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids \u2014 new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/1381612824666180123110042","article-title":"Colchicine pharmacokinetics and mechanism of action","volume":"24","author":"Angelidis","year":"2018","journal-title":"Curr Pharm Des"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jaip.2023.04.002","article-title":"Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions","volume":"11","author":"Bayry","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/art.43403","article-title":"Glucagon-like peptide-1 receptor agonist use and the risk of adverse cardiac and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis","volume":"78","author":"Jorge","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/acr2.11698","article-title":"Metformin in systemic lupus erythematosus: investigating cardiovascular impact and nephroprotective effects in lupus nephritis","volume":"6","author":"Gonzalez Moret","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/art.43037","article-title":"Efficacy and safety of sodium\u2013glucose cotransporter 2 inhibitors for the primary prevention of cardiovascular, renal events, and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: a population-based target trial Emulation","volume":"77","author":"Ma","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R35-20260528","doi-asserted-by":"crossref","first-page":"e000611","DOI":"10.1136\/lupus-2021-000611","article-title":"Metformin improves renal injury of MRL\/lpr lupus-prone mice via the AMPK\/STAT3 pathway","volume":"9","author":"Chen","year":"2022","journal-title":"Lupus Sci Med"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"R37-20260528","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"R39-20260528","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephritis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat Commun"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R42-20260528","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/eji.201041354","article-title":"Plasma cells in systemic lupus erythematosus: the long and short of it all","volume":"41","author":"Liu","year":"2011","journal-title":"Eur J Immunol"},{"key":"R45-20260528","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1093\/rheumatology\/keac037","article-title":"Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis","volume":"61","author":"Mao","year":"2022","journal-title":"Rheumatology"},{"key":"R46-20260528","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation\u2013induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R47-20260528","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3899\/jrheum.180507","article-title":"Longterm data on sirolimus treatment in patients with lupus nephritis","volume":"45","author":"Yap","year":"2018","journal-title":"J Rheumatol"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"R50-20260528","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1515\/rir-2025-0011","article-title":"Sirolimus versus mycophenolate mofetil for the treatment of lupus nephritis: results from a real-world CSTAR cohort study","volume":"6","author":"Bai","year":"2025","journal-title":"Rheumatol Immunol Res"},{"key":"R51-20260528","doi-asserted-by":"crossref","first-page":"108781","DOI":"10.1016\/j.clim.2021.108781","article-title":"Improvement of renal and nonrenal SLE outcome measures on sirolimus therapy \u2013 a 21-year follow-up study of 73 patients","volume":"229","author":"Piranavan","year":"2021","journal-title":"Clin Immunol"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/art.40380","article-title":"Blockade of Treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus","volume":"70","author":"Kato","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R53-20260528","doi-asserted-by":"crossref","first-page":"109939","DOI":"10.1016\/j.clim.2024.109939","article-title":"Immmunometabolism of systemic lupus erythematosus","volume":"261","author":"Furment","year":"2024","journal-title":"Clin Immunol"},{"key":"R54-20260528","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/acr2.11668","article-title":"Redox pathogenesis in rheumatic diseases","volume":"6","author":"Laniak","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"R55-20260528","doi-asserted-by":"crossref","first-page":"e00010","DOI":"10.1097\/IN9.0000000000000010","article-title":"Principles behind SLE treatment with N-acetylcysteine","volume":"4","author":"Nasr","year":"2022","journal-title":"Immunometabolism"},{"key":"R56-20260528","doi-asserted-by":"crossref","first-page":"e70122","DOI":"10.1002\/acr2.70122","article-title":"IgG and IgM anti-phosphatidylserine\/prothrombin complex antibody detection may improve classification accuracy of systemic lupus erythematosus and antiphospholipid antibody syndrome","volume":"7","author":"Donath","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"R57-20260528","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.2147\/JIR.S527859","article-title":"Anti-PS IgG immune complexes impair macrophage phagocytosis in SLE via LOX-dependent oxidative stress","volume":"18","author":"Guan","year":"2025","journal-title":"J Inflamm Res"},{"key":"R58-20260528","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R59-20260528","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1038\/s41467-024-46441-2","article-title":"Rab4A-directed endosome traffic shapes pro-inflammatory mitochondrial metabolism in T cells via mitophagy, CD98 expression, and kynurenine-sensitive mTOR activation","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"key":"R60-20260528","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N -acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R61-20260528","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clim.2015.07.001","article-title":"Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus","volume":"160","author":"Liu","year":"2015","journal-title":"Clin Immunol"},{"key":"R62-20260528","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/art.37893","article-title":"Attention deficit and hyperactivity disorder scores are elevated and respond to N -acetylcysteine treatment in patients with systemic lupus erythematosus","volume":"65","author":"Garcia","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R64-20260528","doi-asserted-by":"crossref","first-page":"e004171","DOI":"10.1136\/rmdopen-2024-004171","article-title":"Recommendations for physical activity and exercise in persons living with systemic lupus erythematosus (SLE): consensus by an international task force","volume":"10","author":"Blaess","year":"2024","journal-title":"RMD Open"},{"key":"R65-20260528","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the nonpharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R66-20260528","doi-asserted-by":"crossref","first-page":"eaax2220","DOI":"10.1126\/scitranslmed.aax2220","article-title":"Gut microbiota dysbiosis and altered tryptophan catabolism contribute to autoimmunity in lupus-susceptible mice","volume":"12","author":"Choi","year":"2020","journal-title":"Sci Transl Med"},{"key":"R67-20260528","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R68-20260528","doi-asserted-by":"crossref","first-page":"e005557","DOI":"10.1136\/rmdopen-2025-005557","article-title":"Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study","volume":"11","author":"Shen","year":"2025","journal-title":"RMD Open"},{"key":"R70-20260528","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ard.2025.06.094","article-title":"POS0734 dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a phase 3 trial","volume":"84","author":"Vital","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R72-20260528","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"R74-20260528","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jcph.6117","article-title":"First-in-human study of the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of DS-7011a, an anti-TLR7 antagonistic monoclonal antibody for the treatment of systemic lupus erythematosus","volume":"65","author":"Senaldi","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"R75-20260528","doi-asserted-by":"crossref","first-page":"e00842","DOI":"10.1002\/prp2.842","article-title":"Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8","volume":"9","author":"Port","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"R76-20260528","doi-asserted-by":"crossref","first-page":"e004701","DOI":"10.1136\/rmdopen-2024-004701","article-title":"Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I\/II study in systemic lupus erythematosus","volume":"10","author":"Tanaka","year":"2024","journal-title":"RMD Open"},{"key":"R77-20260528","doi-asserted-by":"crossref","first-page":"101036","DOI":"10.1016\/j.xcrm.2023.101036","article-title":"Preclinical characterization of the Toll-like receptor 7\/8 antagonist MHV370 for lupus therapy","volume":"4","author":"Hawtin","year":"2023","journal-title":"Cell Rep Med"},{"key":"R78-20260528","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41584-025-01336-4","article-title":"Endosome traffic in rheumatic diseases: mechanistic insights and therapeutic opportunities","volume":"22","author":"Perl","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"R81-20260528","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40265-024-02125-1","article-title":"Xeligekimab: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"R83-20260528","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"R88-20260528","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ard.2025.06.510","article-title":"Pos1160 a phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus","volume":"84","author":"Chindalore","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R90-20260528","doi-asserted-by":"crossref","first-page":"e005742","DOI":"10.1136\/rmdopen-2025-005742","article-title":"Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104\u200aweeks in a long-term extension study","volume":"11","author":"Merrill","year":"2025","journal-title":"RMD Open"},{"key":"R92-20260528","doi-asserted-by":"crossref","first-page":"113040","DOI":"10.1016\/j.intimp.2024.113040","article-title":"Bruton's tyrosine kinase: a promising target for treating systemic lupus erythematosus","volume":"142","author":"Ding","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R94-20260528","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R95-20260528","doi-asserted-by":"crossref","first-page":"e250648","DOI":"10.1001\/jamanetworkopen.2025.0648","article-title":"Mizoribine or cyclophosphamide for lupus nephritis: a randomized clinical trial","volume":"8","author":"Dong","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R98-20260528","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"Van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"R100-20260528","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ard.2025.06.908","article-title":"ABS1156 safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers of Vent-03, a novel cGAS inhibitor for the treatment of systemic lupus erythematosus","volume":"84","author":"Valencia","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:01:19Z","timestamp":1779955279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001160","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]}}}